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Abstract
Introduction: The increasing evidence of SARS-CoV-2 impact on the central nervous
system (CNS) raises key questions on its impact for risk of later life cognitive decline,
Alzheimer’s disease (AD), and other dementia.
Methods: The Alzheimer’s Association and representatives from more than 30
countries—with technical guidance from theWorldHealthOrganization—have formed
an international consortium to study the short-and long-term consequences of SARS-
CoV-2 on the CNS—including the underlying biology that may contribute to AD and
other dementias. This consortiumwill link teams from around theworld coveringmore
than 22 million COVID-19 cases to enroll two groups of individuals including people
with disease, to be evaluated for follow-up evaluations at 6, 9, and 18months, and peo-
plewhoare already enrolled in existing international research studies to add additional
measures andmarkers of their underlying biology.
Conclusions: The increasing evidence and understanding of SARS-CoV-2’s impact on
the CNS raises key questions on the impact for risk of later life cognitive decline, AD,
and other dementia. This program of studies aims to better understand the long-term
consequences that may impact the brain, cognition, and functioning—including the
underlying biology that may contribute to AD and other dementias.
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1 INTRODUCTION
The number is constantly changing, but it seems likely that by the time
the pandemic spends its force about one in every 200 persons world-
wide will have suffered an infection by the new severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2). Most of these individuals
will survive the infection, but the public health impact of the pandemic
may continue as chronic sequelae of coronavirus disease (COVID-19),
resulting in disability or diminished quality of life, now attracting the
term “Longcovid.” Judging by what is known so far, long-term seque-
lae are not just likely to occur, but also likely to affect certain groups
of individuals disproportionately; this only further deepens existing
health disparities. Given the well-established and projected weight of
neuropsychiatric disorders included in the global burden of disability,
it seems particularly appropriate to take stock of what is known about
the deleterious, direct effects of SARS-CoV-2 infection and COVID-19
on the central nervous system (CNS), and to project how these effects
are likely to contribute to the chronic burden of disease globally in
coming years. An equally important but separate issue not covered
in this article is the wider societal impact of the pandemic due to its
likelywider economic, social, and personal effects in the immediate and
longer term.
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2 VIRAL IMPACT ON BRAIN FUNCTIONING
Neurotropic respiratory viruses have long been known to result in
chronic brain pathology.1,2 Paradigmatically, the 1918 influenza pan-
demic was and continues to be suspected as the underlying cause
of encephalitis lethargica;3 emerging movement disorders, profound
sleep cycle abnormalities, and psychotic illness resulted in enormous
burden of disease and untold suffering for affected individuals and
their caregivers. Less spectacular, but perhaps more impactful at the
population level, studies have suggested that common viral infec-
tions such as herpes simplex virus 1 (HSV1) may be associated with
molecular processes in Alzheimer’s disease (AD) dementia in human
brain cells4 and transgenic animal models.5 Several studies have also
suggested an association of HSV1 and cognitive decline.6 Because
brain inflammation accompanies the most common neurodegenera-
tive disorders and may contribute to major psychiatric disorders, the
neurological and psychiatric sequelae of COVID-19 need to be care-
fully tracked.7–14
3 NEUROTROPISM
Coronaviruses, especially β-coronaviruses including SARS-CoV-2, have
been shown in several studies to invade the CNS.7,12,15–17 The CoV
spike glycoprotein binds angiotensin-converting enzyme2 (ACE2)with
high affinity,18,19 and protein cleavage by specific proteases plays a key
role in the brain invasion and virulence of earlier human coronavirus,
andmay play a role in SARS-CoV-2.20
SARS-CoV-2 invades respiratory and gastrointestinal epithelial cells
by binding ACE2 on the cell membrane; ACE2 is also expressed in the
brain, both in neurons and glia. Notably, multiple non-neuronal cell
types present in the olfactory epithelium express two host receptors,
ACE2 and transmembrane serine protease 2 (TMPRSS2) proteases,
that facilitate SARS-CoV-2 binding, replication, and accumulation.21
Intranasal administration of SARS-CoV-2 in mice results in rapid inva-
sion of the brain,22,23 and SARS-CoV-1 viral particles can be detected
post mortem in the cerebrum, but not in the cerebellum, in humans.24
Entry of SARS-CoV-2 into the cells throughmembrane fusionmarkedly
downregulates ACE2 receptors, with loss of the catalytic effect of
these receptors at the external site of the membrane.25,26 Vascular
growth factor (VEGF), which iswidely distributed in the brain,may play
a role in brain inflammation via theACE2pathway.27 Clinical reports of
patients infected with SARS-CoV-2 show that several features associ-
ated with infection and severity of the disease (ie, older age, hyperten-
sion, diabetes, cardiovascular disease) share a variable degree of ACE2
deficiency.25,28–31 In post mortem brain tissue, ACE2 is expressed in the
frontal cortex vasculature, and viral spike proteins cause blood-brain
barrier (BBB) damage in vitro.32
SARS-CoV-2 neurotropism is suspected; it is based on growing evi-
dence from clinical, pathological, andmolecular studies.7,11,12,33–47
First, headache, hypogeusia, and anosmia appear to precede
the onset of respiratory symptoms in the majority of affected
patients, and ataxia and altered mental status have been documented
RESEARCH INCONTEXT
Neurotropic respiratory viruses have long been known to
result in chronic brain pathology including emerging cog-
nitive decline and dementia, movement disorders, and psy-
chotic illness. Because brain inflammation accompanies the
most common neurodegenerative disorders and may con-
tribute to major psychiatric disorders, the neurological and
psychiatric sequelae of COVID-19 need to be carefully
tracked.
independent of multiorgan failure.12,21,38,48–52 There have also been
documented cases of acute encephalopathy and meningoencephalitis
associated with detection of SARS-CoV-2 RNA in the cerebrospinal
fluid (CSF).7,53–57 SARS-CoV-2 can also be found in the brain post
mortem.56 Further, pan-encephalitis and diffuse petechial hemorrhage
of the entire brain have been reported,58 particularly perivascular and
interstitial encephalitis in the brain stem,58,59 in some patients.60
In addition, respiratory problems due to SARS-CoV-2 are thought
to be due in part to brain-stem dysregulation,11,12,61–64 as are pos-
sibly some of the gastrointestinal symptoms.65 Neurological symp-
toms may occur in their first 1 to 2 days of the clinical symp-
tomatic phase, and cerebrovascular accidents are common within
2 weeks of the onset of the symptomatic phase.51,65–74 While case
series of para-infectious or post-infectious acute neuroinflammatory
syndromes such as acute disseminated encephalomyelitis (ADEM)
are reported in association with SARS-CoV-2 infection,51,75,76 many
patients with COVID-19 on intensive care units (ICUs) have corti-
cospinal tract signs.44 The absence of SARS-CoV-2 viral load in the
CSF and the presence of oligoclonal bands in the CSF and serum of
some patients suggest immune-mediated response that is not limited
to intrathecal production of immunoglobulins.8,44,56 Other common
neurological manifestations include meningitis and acute demyelinat-
ing polyneuropathy.38,49–51,68,77,78 New onset seizures, sometimes fol-
lowed by anosmia, have also been reported in SARS-CoV-2–confirmed
infections.12,68,79–83 The mechanisms of causation of seizures are
probably complex, and may include cortical irritation due to hemor-
rhages, inflammation, ormetabolic changes.12,80 Sporadic epileptiform
discharges were detected in nearly half of COVID-19 patients in inten-
sive care.81
Delirium can be the only presenting symptom of SARS-CoV-2
infection84–86 even in younger patients.56 The incidence of delirium
in severely ill COVID-19 patients on ICUs is reported to be as high
as 84%,44 of which more than two thirds exhibit hyperactive delirium,
despite receiving high sedation and neuroleptics.44 The overall inci-
dence of delirium across the clinical spectrum from mild to severely
ill patients with COVID-19 is unknown. Because many patients with
COVID-19 are mechanically ventilated,87–89 a substantial proportion
of patients with COVID-19 are likely to experience delirium with
a currently unknown long-term outcome. In elderly patients with
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dementia, delirium is a very frequent presenting symptom of SARS-
CoV-2 infection90 and carries a higher short-termmortality rate.91
Delirium in COVID-19 may be a feature of primary encephalopa-
thy due to the direct intracerebral viral invasion.92 Alternatively,
secondary encephalopathy may be associated with neuroinflam-
matory response to SARS-Cov-2;93,94 immune-mediated systemic
response;8,95,96 or independent complications of hypoxemia, sepsis,
hypoperfusion, severe metabolic illness, and pharmacological side
effects.
As evidence accumulates regarding viral neuroinvasion, there are
several routes for possible transmission, including trans-synaptic
transfer across infected neurons in splacnic nerves,11,12,62,97 entry
via the olfactory nerve,21,98 infection of vascular endothelium, leuko-
cyte migration across the BBB, and/or a conjunctival route.11,99,100
From the olfactory bulb, SARS-CoV-2 may target the deeper parts
of the brain including the thalamus and brain stem by trans-synaptic
transfer described for many other viral diseases.11,101 In some indi-
viduals, SARS-CoV-2 infection triggers a massive release of cytokines,
chemokines, and other inflammation signals leading to BBB dysfunc-
tion, injury to astrocytes, activation of microglia and astrocytes pro-
moting neuroinflammation and neuronal death.11,62,102–104 Immune
response and excessive inflammation in COVID-19 may also acceler-
ate the progression of brain inflammatory neurodegeneration; elderly
individuals aremore susceptible to severe outcomes after SARS-CoV-2
infection.105
Because the entry points of viral invasion into the brain have
direct connections to brain stem and thalamic structures, ensuing
dysfunction may result in sensorimotor, mental, and behavioral
disorders.11,68,106–108 Indeed, in a case series from the UK acute
alteration in personality, behavior, cognition, or consciousness was
the second most common presentation of COVID-19, often occurring
in younger individuals; nearly half of these individuals had new-onset
psychosis, while the rest had neurocognitive (dementia-like) syndrome,
or affective disorders.51 Autoimmune encephalitides associated with
antibodies against neuronal cell-surface or synaptic proteins; in
those with new-onset psychosis, higher prevalence of antibodies
against four other coronaviruses strains have been found,56 and at
least one confirmed case of anti-n-methyl-d-aspartate antibodies
encephalitis associated with COVID-19 was reported.109 Further,
reports of individuals presenting with clinical-radiological features of
limbic encephalitis and little systemic symptoms of COVID-1956,110
suggests immune-mediated response to SARS-CoV-2.109 Taken
together, the evidence suggests a possible mechanism for SARS-CoV-2
encephalopathy and psychosis.
4 BRAIN IMAGING
Abnormal brain imaging has emerged as a major feature of COVID-
19 from all parts of the world.111 Structural brain magnetic resonance
imaging (MRI) revealed parenchymal brain abnormalities, subcortical
micro- and macro-bleeds, cortico-subcortical edema, nonspecific deep
white matter changes, and asymmetric olfactory bulbs post mortem,112
and similar findings during hospital admission.113–119,94,120 The abnor-
mal imaging has been seen in an individual whose only symptom was
anosmia.121 The most common MRI findings from patients admit-
ted to ICUs include cortical signal abnormalities on fluid-attenuated
inversion recovery images, accompanied by cortical diffusion restric-
tion or leptomeningeal enhancement, which may reflect infectious or
autoimmuneencephalitis, seizures, hypoglycemia, or hypoxia.122 Acute
demyelinating lesions also have been described and have been visual-
ized on images.76,123–125
5 POSSIBLE DETERMINANTS
Different host immune responses to SARS-CoV-2 infection may par-
tially explain why males and females, young and old persons infected
with this virus have markedly distinct disease severity.126 In fact, C-
reactiveprotein127 and ferritin128 levelswereassociatedwithelevated
risk of COVID-19 in a dose-dependent manner, and N-terminal pro-
brain natriuretic peptide (NT-proBNP) was associated with increased
mortality in COVID-19 pneumonia.129,130 Concomitant cardiac dis-
ease has an extremely poor prognosis, with higher mortality, thrombo-
embolic events, and septic shock rates.131
Among hospitalized COVID-19 cases, physical inactivity, smok-
ing, and obesity but not heavy alcohol consumption were related to
increased rates of hospital admission.127 Diabetes mellitus increases
risk for dementia as well as of severe outcomes after SARS-CoV-2
infection, and is highly prevalent in certain demographics such as Black
American/African Americans and Latino/Hispanic Americans,105 and
the same demographic groups appear to be at higher risk of neurolog-
ical complications of COVID-19.132 Disparities in COVID-19 hospital-
izations andmortality according to ethnicity remain present, even after
correcting for neighborhood, household crowding, smoking, body size,
diabetes, andmental illness.133
6 IMPLICATIONS FOR NEUROPSYCHIATRIC
DISORDERS
Olfactory deficits have been previously reported for several
viral infections,12,134 and are characteristic of neurodegenera-
tive disorders.135–139 Notably, anosmia is linked to high levels of
interleukin-6, an inflammatory mediator causally involved in brain dis-
orders whose actions are blocked by tocilizumab as part of COVID-19
treatment.140
Systematic reviews141,142 andmeta-analysis data143,144 have firmly
established incident and prevalent stroke as independent risk factors
of dementia. Likewise, typical risk factors for stroke increase the odds
of dementia including coronary heart disease and carotid stenosis,145
as well as atrial fibrillation,146 stage 1 midlife hypertension,147 and
hyperhomocysteinemia.148 Furthermore, MRI features of cerebral
small vessel disease, ie, whitematter hyperintensities, lacunes, microb-
leeds, perivascular spaces, and cerebral atrophy were additively
associated with dementia and cognitive decline.149–151 Therefore, it
seems likely to expect that COVID-19–related cardiovascular and
4 DE ERAUSQUIN ET AL.
F IGURE 1 Consortium participants. Colored countries in themap represent those with at least one academic institution participating in the
Consortium for Chronic Neuropsychiatric Sequelae of SARS-CoV-2
cerebrovascular disease will also contribute to a higher long-term risk
of cognitive decline and dementia in recovered individuals.
Multiple lines of evidence suggest that viral infections of the brain
may impact a person’s risk for AD or Parkinson’s disease. The present
pandemic provides a unique—if unwelcome—opportunity to test the
role of neurotropic viruses in a prospective fashion in individuals
that have recovered fromCOVID-19.152,153 Themechanisms by which
neurological abnormalities result from COVID-19 remains to be fully
established. Direct effects of SARS-CoV-2 itself on neuronal function
and survival or glial reactivity, exaggerated cytokine responses, or anti-
neuronal antibodies are all likely to contribute, as are the sequelae
from cerebrovascular accidents. As pointed out above, the experience
of pandemics caused by neurotropic respiratory viruses in the past—
as well as the emerging data and observations of clinicians over the
past several months—strongly supports an expectation of increased
neuropsychiatric sequelae, including cognitive decline, motor impair-
ment, and affective and psychotic disorders, in addition to demyelinat-
ing processes or cerebrovascular disease that occur during the acute
viral infection, or may follow infection in recovered individuals.154
7 PSYCHIATRIC DISORDERS
Psychiatric distress and acquired cognitive deficits after COVID-19
will likely have complex, bidirectional relationships. Impaired cogni-
tive abilities may cause poor occupational and functional outcomes
that precipitate or exacerbate mental health concerns, and poor men-
tal health may likewise contribute to cognitive dysfunction.155 The
SARS-CoV-1 epidemic was associated with psychiatric complications.
COVID-19 patients found a high level of post-traumatic stress symp-
toms and significantly higher level of depressive symptoms. Patients
with preexisting psychiatric disorders reported worsening of psychi-
atric symptoms.156 After the coronavirus pandemics in 2002 and2012,
one in five recovered individuals reported depressed mood, insomnia,
anxiety, irritability, fatigue, and in one study traumatic memories and
sleep disorder were frequently reported. The meta-analysis indicated
that in the post-illness stage the point prevalence of post-traumatic
stress disorder was 32.2%, depression was 14.9%, and anxiety disor-
ders was 14.8%.157
8 COGNITIVE DECLINE AND MOTOR
IMPAIRMENT
COVID-19 results in high levels of proinflammatory cytokines, acute
respiratory distress, and hypoxia, each of which may contribute
to cognitive decline both in healthy and in already predisposed
individuals.14,158 After the coronavirus pandemics in 2002 and 2012,
one in five recovered individuals reportedmemory impairment,157 and
an early report found that one in three individuals with COVID-19 had
dys-executive syndrome at the time of hospital discharge.157 Impaired
cognitive abilities may cause poor occupational and functional out-
comes for individuals recovered from COVID-19 that precipitate or
exacerbate mental health concerns, and poor mental health may like-
wise contribute to cognitive dysfunction.155
Influenza epidemics are associated with neurological manifesta-
tions, and the H5N1 virus reportedly induces Parkinsonian pathol-
ogy in mice, both findings possibly explained by the activation of
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TABLE 1 COVID-19 cases per country. Numbers represent







































inflammatory pathways.159 However, the exact mechanisms of these
effects and whether coronaviruses show a similar action remain
unclear. About half of hospitalized patients are >55 years; the result-
ing higher age-related risk of neurodegenerative disorders is a good
setting to investigate triggering and double-hit mechanisms previously
hypothesized for viral infections.160 Despite the higher mortality rate,
a majority of cases are expected to recover and survive from this viral
outbreak. A natural decline in ACE2 expression and the subsequent
pro-inflammatory profile with aging may explain the increased sever-
ity and comorbid diabetic and hypertensive complications observed in
older adults. There arepotential long-term implicationsof SARS-CoV-2
infection in relation to accelerated brain aging, neurovascular coupling,
and age-related neurodegenerative disorders.
As described above, coronaviruses can cause demyelination, neu-
rodegeneration, and cellular senescence. SARS-CoV-2 specifically can
infect endothelial cells expressing ACE2 potentially leading to further
deterioration of this vascular architecture. The resulting hypoperfu-
sion may restrict energy substrates essential for maintaining neuronal
networks thereby accelerating cognitive decline in the elderly. Dam-
age to limbic and cortical regions could cause retrograde and antero-
grade amnesia. As a result ofACE2downregulation, SARS-CoV-2 infec-
tion in older adults induces aggressive secretion of pro-inflammatory
cytokines.
Pro-inflammatory cytokines increase oxidative stress that damages
cellular membranes and downregulates surface expression of excita-
tory amino acid transporters that are necessary for terminating glu-
tamatergic signaling. The resulting elevated glutamate levels can lead
to an excitotoxic environment precipitating the neuronal loss and ini-
tiating a vicious feed-forward cycle that causes further damage to the
surrounding parenchyma. Viral entry into neurons may create a cyto-
toxic insult and initiate apoptotic pathways or create an excitatory–
inhibitory imbalance. This pathway is already postulated to play a role
in several neurodegenerative diseases including AD and Parkinson’s
disease. A slow infiltration throughout the CNSmay precipitate under-
lying pathologies associated with age-related neurodegenerative dis-
orders months or years after acute viral infection. The neuroinvasive
potential of SARS-CoV-2 may result in senescence of several different
CNS cell types including oligodendrocytes, astrocytes, and neural stem
cells that can differentiate into neurons that integrate into the granule
layer. Viral aggravation of underlying neuropathology has the poten-
tial to hasten the onset of or further deteriorate motor and cognitive
deficits.161
9 CONCLUSION AND NEXT STEPS
The increasing evidence and understanding of SARS-CoV-2’s impact
on the CNS raises key questions on the impact for risk of later
life cognitive decline, AD, and other dementia. Scientific leaders,
including the Alzheimer’s Association and representatives from more
than 30 countries—with technical guidance from the World Health
Organization—have formed an international, multidisciplinary consor-
tium to collect and evaluate the short- and long-term consequences of
SARS-CoV-2 on theCNS. This programof studies aims to better under-
stand the long-term consequences that may impact the brain, cogni-
tion, and functioning—including the underlying biology that may con-
tribute to AD and other dementias.
This consortium will link study teams from around the world
(Figure 1) covering more than 22 million cases at the time of submis-
sion (Table 1) to enroll two groups of individuals including people with
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confirmed cases of COVID-19 sampled from hospitals that have been
discharged to be evaluated for follow-up at 6, 9, and 18 months, and
people who are already enrolled in existing international research
studies to add additional measures and markers of their underlying
biology.
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